Enrolment delays and protocol amendments in clinical trial enrolment cost the biopharmaceutical industry approximately $20 billion a year. To make matters worse, nearly half of these corrections are avoidable, particularly those caused by patient recruitment and retention issues.
To remedy these issues, R&D teams are evaluating their strategies in approaching recruitment and retention issues towards a more patient-centric approach. These strategies typically have two desired outcomes:
Our leadership team have watched the life Sciences industry develop and have a joint vision of how to push it forward. They challenge us to create better results for our clients, to come up with ways to revolutionize the industry and to redefine our place in it.
Morbi cursus varius ex id rutrum. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Proin metus libero, auctor vel tempor non, venenatis posuere ipsum. Vivamus vulputate sapien augue. Nunc in nisl rhoncus, dapibus purus nec, consequat magna. Nullam dapibus lorem et magna tristique porta. Phasellus pharetra sem ut nisl tristique eleifend nec non est. Nam euismod ex quis elit tristique sodales.
Aenean nec sodales purus. Nunc vel risus at lacus bibendum auctor:
Quisque volutpat, turpis eu elementum suscipit, sapien dui sollicitudin erat, in pulvinar lorem nisi a lectus. Sed nec arcu eu ex tincidunt gravida. Nam dignissim orci et velit tincidunt, pellentesque ultrices lectus interdum. Sed venenatis in eros at elementum.
Sed varius sapien maximus, molestie nunc sit amet, elementum leo. Quisque condimentum varius erat, in bibendum sem tristique id. Duis ac sagittis risus. Vivamus mattis, nulla pharetra rutrum feugiat, velit leo tincidunt eros, vitae dignissim ex justo in nulla.
Our leadership team have watched the life Sciences industry develop and have a joint vision of how to push it forward. They challenge us to create better results for our clients, to come up with ways to revolutionize the industry and to redefine our place in it.